Palisade Bio Inc (NASDAQ: PALI) shares are trading lower by 31.82% to $2.40 after the company announced a $6 million registered direct offering and concurrent private placement priced above the market under Nasdaq rules.
Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $125 to $128.